This company is no longer active
Reneo Pharmaceuticals Management
Management criteria checks 4/4
Reneo Pharmaceuticals' CEO is Greg Flesher, appointed in Nov 2020, has a tenure of 3.92 years. total yearly compensation is $569.70K, comprised of 99% salary and 1% bonuses, including company stock and options. directly owns 0.069% of the company’s shares, worth $42.22K. The average tenure of the management team and the board of directors is 3.9 years and 3.8 years respectively.
Key information
Greg Flesher
Chief executive officer
US$569.7k
Total compensation
| CEO salary percentage | 99.0% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.07% |
| Management average tenure | 3.9yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
Oct 03
Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth
Apr 25Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
Nov 22We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
Aug 09Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
Apr 22We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth
Jan 20Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation
Oct 02Our First Look At Reneo Pharmaceuticals
Aug 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$57m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$570k | US$564k | -US$77m |
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$54m |
| Dec 31 2022 | US$1m | US$545k | -US$52m |
| Sep 30 2022 | n/a | n/a | -US$49m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$5m | US$475k | -US$40m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$22m |
| Dec 31 2020 | US$529k | US$79k | -US$19m |
Compensation vs Market: Greg's total compensation ($USD569.70K) is about average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.
CEO
Greg Flesher (54 yo)
3.9yrs
Tenure
US$569,704
Compensation
Mr. Gregory J. Flesher, also known as Greg, serves as President, Director and Chief Executive Officer of Reneo Pharmaceuticals, Inc since November 2020. He had been Consultant of Eledon Pharmaceuticals, In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 6.8yrs | US$215.13k | 1.48% $ 900.5k | |
| President | 3.9yrs | US$569.70k | 0.069% $ 42.2k | |
| Chief Medical Officer | 6.8yrs | US$466.23k | 0% $ 0 | |
| SVP of Finance & Administration and Principal Financial & Accounting Officer | no data | no data | no data | |
| Chief Operating Officer | 2.6yrs | US$781.47k | 0.073% $ 44.5k |
3.9yrs
Average Tenure
58.5yo
Average Age
Experienced Management: RPHM's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 6.8yrs | US$215.13k | 1.48% $ 900.5k | |
| President | 3.9yrs | US$569.70k | 0.069% $ 42.2k | |
| Independent Director | 6.8yrs | US$165.13k | 0% $ 0 | |
| Director | 6.8yrs | US$155.13k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$166.63k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$141.47k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$115.13k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$175.13k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$170.63k | 0% $ 0 |
3.8yrs
Average Tenure
51yo
Average Age
Experienced Board: RPHM's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/06 19:25 |
| End of Day Share Price | 2024/10/04 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Reneo Pharmaceuticals, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Zemansky | BofA Global Research |
| Xiaodong Zhang | H.C. Wainwright & Co. |